Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NP202 for paroxysmal atrial fibrillation in patients with implantable cardiac devices
ACTRN12618001692224Phase 2Recruiting
- Sponsor
- John Hunter Hospital
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NP202 in Atrial fibrillation (AFib) (2 arms), sponsored by John Hunter Hospital. Primary endpoint: Change in atrial fibrillation burden. Started Jun 2018; status: recruiting.
02
Drugs
NP202
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ACTRN12618001692224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001692224.